UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE...
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER...
AMSTERDAM, THE NETHERLANDS and BRIDGEWATER, NJ -- (Marketwire) -- 12/01/10 -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...
AMSTERDAM, THE NETHERLANDS -- (Marketwire) -- 11/05/10 -- Eurand N.V. (NASDAQ: EURX) Recent Highlights: Record revenues of EUR 41.7 million ($56.7...
YARDLEY, PA -- (Marketwire) -- 11/01/10 -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, is scheduled to participate in...
AMSTERDAM, THE NETHERLANDS -- (Marketwire) -- 10/21/10 -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, will host a...
YARDLEY, PA -- (Marketwire) -- 10/21/10 -- Eurand Pharmaceuticals, Inc., a subsidiary of global specialty pharmaceutical company Eurand N.V...
PHILADELPHIA, PA -- (Marketwire) -- 09/24/10 -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, announced today that...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.